Elanco Animal Health Incorporat (ELAN) Stock Price & How to Invest

Elanco Animal Health was spun out of Eli Lilly in 2018 and became one of the largest standalone animal health companies in the world after buying Bayer Animal Health in 2020. The business splits roughly into Pet Health (flea and tick parasiticides such as Credelio and Seresto, the dermatology drug Zenrelia, pain products such as Galliprant) and Farm Animal (cattle, poultry, swine and aqua-adjacent products including Rumensin, Experior and the methane-reducing feed additive Bovaer in the US). Revenue comes through veterinary clinics, distributors, retail and e-commerce channels, and from farm producers who buy on economics rather than sentiment, which makes the two halves behave quite differently across a cycle.

The investment picture is a product-cycle story layered on top of a deleveraging story. For several years Elanco was the underperformer in animal health: contract manufacturing separation costs, generic pressure on older parasiticides, and a heavy debt load from the Bayer acquisition all weighed on results while Zoetis compounded ahead of it. That changed with the launches of Credelio Quattro and Zenrelia, both of which crossed the $100 million blockbuster mark unusually fast, and with steady debt paydown helped by asset sales. Second quarter 2026 results showed revenue of ~$1.37 billion with organic constant-currency growth of ~8%, adjusted EBITDA up ~21% to ~$288 million, and full-year 2026 guidance raised to ~$5.09 billion to ~$5.14 billion in revenue. The stock has re-rated substantially on that, so the shares now price in a fair amount of continued execution.

Competition is the central risk: Zoetis is larger, better capitalized and defends the parasiticide and dermatology categories aggressively, and Merck, Boehringer Ingelheim and others are active in the same clinics. Zenrelia carries a boxed warning related to use around modified live vaccines, which has slowed some veterinary adoption relative to the incumbent it competes with. Debt remains high in absolute terms at roughly ~$3.7 billion gross, so a growth stumble hits equity value harder than it would at an unlevered peer. Legacy products including Seresto and older parasiticides face generic and private-label erosion that can offset new launches. Farm animal demand tracks herd sizes, feed costs and export markets, and a large share of revenue is earned outside the US, which adds currency translation swings to reported results.

14 analysts publish price targets on ELAN, averaging $31.21 against a $22.12 price as of August 2026, or +41.1%. The published targets run from $26.00 to $34.00, a narrow spread, and the ratings split 15 buy, 2 hold, 0 sell. Over the last six months there have been 10 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ELAN forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Elanco Animal Health Incorporat. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The new pet blockbusters. Credelio Quattro, a broad-spectrum parasiticide aimed squarely at the market Zoetis dominates with Simparica Trio, reached blockbuster status in under eight months and has penetrated more than ~40% of US clinics. The most optimistic published target, $34.00, assumes this works close to its best case.

The case against. Competition is the central risk: Zoetis is larger, better capitalized and defends the parasiticide and dermatology categories aggressively, and Merck, Boehringer Ingelheim and others are active in the same clinics. The most pessimistic target, $26.00, is roughly what ELAN is worth if this bites instead.

Read the full bull and bear case on ELAN, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Elanco Animal Health Incorporat's investor relations page or your broker.

• Revenue (TTM): ~$4.9B
• Q2 2026 revenue: ~$1.37B, up ~10% reported and ~8% organic constant currency
• FY 2026 revenue guidance: ~$5.09B to ~$5.14B
• FY 2026 adjusted EBITDA guidance: ~$1.01B to ~$1.035B
• FY 2026 adjusted EPS guidance: ~$1.10 to ~$1.16
• Market cap / net debt: ~$12.8B market cap against ~$3.16B net debt, ~3.1x net leverage

At roughly $27 a share the stock trades near the low-to-mid 20s times the midpoint of 2026 adjusted EPS guidance, and closer to ~15x to ~16x enterprise value to adjusted EBITDA once the ~$3.2 billion of net debt is included. That is a discount to Zoetis on most multiples, which reflects the leverage and the slower legacy portfolio rather than a disagreement about the new launches. The shares have roughly doubled over the past year, so much of the easy re-rating from deeply-out-of-favor levels has already happened.

Other names that sit close to ELAN: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get ELAN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ELAN sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ELAN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

ELAN is an animal health turnaround where the new drug launches are working, and the remaining question is whether growth and cash flow arrive fast enough to keep shrinking the debt built up from the Bayer Animal Health deal.

Whether ELAN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ELAN a buy or a sell?, and where the stock could go from here in the ELAN stock forecast.

For income investors, whether ELAN pays a dividend and how the payout looks is covered in does ELAN pay a dividend? And to weigh ELAN against a peer, read the full side-by-side comparisons: ELAN vs ZTS and ELAN vs CHWY.